22nd Century Group Inc represents a commitment to advancing plant-based research and technology to develop unique and safer tobacco and cannabis products. The company focuses on enhancing the understanding of the genetic factors that influence the levels of nicotine and other important compounds in various plants. By employing their proprietary technology, 22nd Century Group Inc aims to create reduced nicotine tobacco cigarettes, potentially leading to a positive impact on public health. With a dedication to responsible corporate practices, the company strives to contribute to a smoke-free future while promoting sustainability and transparency in its operations.

22nd Century Group Inc primarily operates in the United States.

22nd Century Group Inc has achieved significant milestones throughout its existence. One noteworthy accomplishment is the development of proprietary technology that allows their scientists to increase or decrease the level of nicotine in tobacco plants. This breakthrough has positioned the company as a leader in reduced nicotine content cigarettes and has garnered attention from regulators and tobacco control advocates. Additionally, 22nd Century Group Inc has successfully secured distribution agreements, bolstered its intellectual property portfolio, and conducted multiple clinical studies to support the potential health benefits of their products. These achievements demonstrate the company's commitment to innovation and its ongoing efforts to revolutionize the tobacco industry.

22nd Century Group Inc is a leading plant biotechnology company that specializes in developing and commercializing disruptive technologies for modifying the nicotine content in tobacco plants and engineering hemp plants to produce cannabinoids in cannabis. Founded in 1998, the New York-based company has been at the forefront of health and wellness innovation in the tobacco and cannabis industries. With a mission to reduce nicotine addiction and create alternative tobacco products, 22nd Century Group Inc is committed to revolutionizing the way people consume nicotine. Their extensive research and development efforts have positioned them as a key player in the field of plant science.

The main competitors of 22nd Century Group Inc in the market include British American Tobacco plc (BAT) and Philip Morris International Inc. (PMI).

22nd Century Group Inc is primarily active in the industries of biotechnology and tobacco.

The business model of 22nd Century Group Inc revolves around developing and commercializing disruptive biotechnology and plant biotechnology. The company focuses on creating proprietary technology platforms that can enhance the taste, smell, and effects of nicotine in tobacco plants. With the aim of reducing nicotine addiction, 22nd Century Group Inc also seeks to modify the levels of cannabinoids in cannabis plants for medical and therapeutic uses. By leveraging their advanced technology, the company intends to address the increasing demand for modified tobacco and cannabis products.

De 22nd Century Group K/W is -0,00.

De 22nd Century Group KUV is 0,00.

De AlleAktien Kwaliteitsscore voor 22nd Century Group is 4/10.

De verwachte 22nd Century Group omzet is 34,20 mln. USD.

De verwachte 22nd Century Group winst is -535,16 mln. USD.

22nd Century Group Inc is a leading company in the production of tobacco and hemp products, based in Williamsville, New York. Its business model is focused on the development and marketing of products that cater to consumer needs. The company offers a wide range of non-smoking, tobacco, and hemp products across various categories. 1. Tobacco products: The 22nd Century Group manufactures tobacco products with a difference - it develops and produces tobacco that contains only a fraction of the nicotine levels found in the market. With this product, the company offers a healthier alternative for individuals looking to minimize tobacco consumption. 2. Hemp products: The company also specializes in the development of hemp products. It provides a wide range of products such as CBD cigarettes, hemp-based tobacco alternatives, chewing gums, and more. The company sources its raw materials from organically controlled cultivation and ensures that its products comply with the highest quality standards. 3. Life Sciences: 22nd Century Group also has a division focused on the life science segment. Here, the company works on the development of medications for the treatment of nicotine addiction and other medical conditions. It collaborates closely with leading universities and research institutions to expand its knowledge and resources. 4. Licensing: The company also operates a licensing business that allows partners to leverage its patented technologies. By licensing its technologies, 22nd Century Group can maximize revenues while strengthening its position in the market. To strengthen its market position and foster growth, 22nd Century Group relies on innovative and creative measures. The company also utilizes digital methods such as SEO, PPC campaigns, and other marketing strategies to promote its products. Communication with its customers is another critical factor in improving its business model. In addition, 22nd Century Group focuses on effective corporate management to reduce operating costs and increase profitability. Overall, 22nd Century Group is an innovative company specializing in the development of consumer-oriented products. With a wide range of tobacco, hemp, and life science products, the company offers a diverse range of opportunities. Licensing also forms an essential part of its business model. As part of its strategy, 22nd Century Group emphasizes top-quality products, research findings, and developments that enhance product positioning to stimulate growth and maintain a strong market position.

22nd Century Group keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor 22nd Century Group of het bedrijf keert geen dividend uit.

De ISIN van 22nd Century Group is US90137F1030.

Het WKN van 22nd Century Group is A1W2NQ.

De ticker van 22nd Century Group is XXII.

Binnen de laatste 12 maanden betaalde 22nd Century Group een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal 22nd Century Group naar verwachting een dividend van 0 USD betalen.

De dividendrendement van 22nd Century Group is momenteel .

22nd Century Group betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

22nd Century Group betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

22nd Century Group wordt toegewezen aan de sector 'Niet-cyclische consumptiegoederen'.

Om het laatste dividend van 22nd Century Group van 26-11-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 26-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 26-11-2024.

In het jaar 2023 heeft 22nd Century Group 0 USD aan dividenden uitgekeerd.

De dividenden van 22nd Century Group worden in USD uitgekeerd.